Literature DB >> 25577298

Aligning policy to promote cascade genetic screening for prevention and early diagnosis of heritable diseases.

Rani George1, Karen Kovak, Summer L Cox.   

Abstract

Cascade genetic screening is a methodology for identifying and testing close blood relatives of individuals at increased risk for heritable conditions and follows a sequential process, minimizing testing costs and the number of family members who need to be tested. It offers considerable potential for cost savings and increased awareness of heritable conditions within families. CDC-classified Tier 1 genomic applications for hereditary breast and ovarian cancer syndrome (HBOC), Lynch Syndrome (LS), and familial hypercholesterolemia (FH) are recommended for clinical use and support the use of cascade genetic screening. Most individuals are unaware of their increased risk for heritable conditions such as HBOC, LS, and FH. Consistent implementation of cascade genetic screening could significantly increase awareness and prevention of heritable conditions. Limitations to effective implementation of cascade genetic screening include: insufficient genetic risk assessment and knowledge by a majority of healthcare providers without genetics credentials; a shortage of genetic specialists, especially in rural areas; a low rate of reimbursement for comprehensive genetic counseling services; and an individual focus on prevention by clinical guidelines and insurance coverage. The family-centric approach of cascade genetic screening improves prevention and early diagnosis of heritable diseases on a population health level. Cascade genetic screening could be better supported and augmented through changes in health policy.

Entities:  

Mesh:

Year:  2015        PMID: 25577298     DOI: 10.1007/s10897-014-9805-5

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  35 in total

1.  What Is Familial Hypercholesterolemia, and Why Does It Matter?

Authors:  Amit V Khera; Robert A Hegele
Journal:  Circulation       Date:  2020-06-01       Impact factor: 29.690

2.  Moving the Needle on Action Around Evidence-Based Screening for Hereditary Conditions: Preparing State Chronic Disease Directors to Advance Precision Public Health.

Authors:  Amy Ponte; Samantha Greenberg; Karen Greendale; Laura Senier
Journal:  Public Health Rep       Date:  2019-03-21       Impact factor: 2.792

3.  The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice.

Authors:  Fred H Menko; Jacqueline A Ter Stege; Lizet E van der Kolk; Kiki N Jeanson; Winnie Schats; Daoud Ait Moha; Eveline M A Bleiker
Journal:  Fam Cancer       Date:  2019-01       Impact factor: 2.375

Review 4.  Family-Specific Variants and the Limits of Human Genetics.

Authors:  Brian H Shirts; Colin C Pritchard; Tom Walsh
Journal:  Trends Mol Med       Date:  2016-10-11       Impact factor: 11.951

5.  Cancer Genetic Counseling and Testing: Perspectives of Epithelial Ovarian Cancer Patients and Gynecologic Oncology Healthcare Providers.

Authors:  Margaret I Liang; Deanna H Wong; Christine S Walsh; Robin Farias-Eisner; Joshua G Cohen
Journal:  J Genet Couns       Date:  2017-08-07       Impact factor: 2.537

6.  Association of Rare Pathogenic DNA Variants for Familial Hypercholesterolemia, Hereditary Breast and Ovarian Cancer Syndrome, and Lynch Syndrome With Disease Risk in Adults According to Family History.

Authors:  Aniruddh P Patel; Minxian Wang; Akl C Fahed; Heather Mason-Suares; Deanna Brockman; Renee Pelletier; Sami Amr; Kalotina Machini; Megan Hawley; Leora Witkowski; Christopher Koch; Anthony Philippakis; Christopher A Cassa; Patrick T Ellinor; Sekar Kathiresan; Kenney Ng; Matthew Lebo; Amit V Khera
Journal:  JAMA Netw Open       Date:  2020-04-01

7.  Implementing Cancer Genomics in State Health Agencies: Mapping Activities to an Implementation Science Outcome Framework.

Authors:  Ridgely Fisk Green; Marie T Kumerow; Juan L Rodriguez; Siobhan Addie; Sarah H Beachy; Laura Senier
Journal:  Public Health Genomics       Date:  2020-09-17       Impact factor: 2.000

8.  A Pragmatic Testing-Eligibility Framework for Population Mutation Screening: The Example of BRCA1/2.

Authors:  Ana F Best; Margaret A Tucker; Megan N Frone; Mark H Greene; June A Peters; Hormuzd A Katki
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-01-28       Impact factor: 4.254

Review 9.  Management of patients with familial hypercholesterolaemia.

Authors:  Željko Reiner
Journal:  Nat Rev Cardiol       Date:  2015-06-16       Impact factor: 32.419

Review 10.  The Present and the Future of Genetic Testing in Familial Hypercholesterolemia: Opportunities and Caveats.

Authors:  Amanda J Hooper; John R Burnett; Damon A Bell; Gerald F Watts
Journal:  Curr Atheroscler Rep       Date:  2018-05-19       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.